On recommendation 1 on a secure Associated Country status for Framework Programme 9, the Government said:
We would like to ensure Framework Programme 9 remains open to our association. We recognise that such an association would necessarily involve an appropriate financial contribution in line with other associates and would like to discuss the details.
Overall, our priorities for the programme lie in three primary areas. The first being that the programme remains focussed on excellence, EU- added value and openness to the world (as outlined in our position paper). Secondly, we want to ensure appropriate financial contributions for associated countries. Finally, confirmation that the programme allows associated countries a suitable degree of influence, in recognition of the benefits they bring to the programme, and in line with their financial contributions.
On recommendation 2 on immigration arrangements to support science and innovation, the Government said:
We are carefully considering a range of options for the future immigration system and are keen to ensure that decisions on our future immigration arrangements are based on evidence.
We believe that the timescales set out for the MAC report are appropriate to meet the scale of the task set and have no plans to ask the MAC to expedite their review. The Government will have plenty of time to take account of the MAC’s advice when making any final decisions about our future immigration system.
On recommendation 3 on clinical trials:
Regardless of the outcome of the negotiations, the Government will ensure that after the end of the Implementation Period, our national legislation will protect the rights, safety, dignity and well-being of research participants in the UK to the same degree as research participants in other EU Member States. Our national legislation will reflect globally acceptable standards of good clinical practice and will help us to collaborate with regulators across the world to share information about patient safety. The Government will also continue to support patients and stakeholders with their planning.
On recommendation 4 on an early deal for science:
The UK has consistently expressed its desire for continued collaboration on S&I with the EU. This position was reinforced by the Prime Minister on 2 March 2018 who reiterated that the UK is committed to establishing a ‘far-reaching science and innovation pact with the EU, facilitating the exchange of ideas and researchers.’ We would like to discuss possible options as soon as possible.
The original report can be found here.